WRAPUP 3-Greek finance minister quits to smooth talks after thunderous 'No' *European partners say await new proposals from Greece. ATHENS/ FRANKFURT, July 6- Greece's outspoken finance minister resigned on Monday, removing a major obstacle to any deal to keep Athens in the euro zone after Greeks voted resoundingly to back the government in rejecting the austerity terms of a bailout. Yanis Varoufakis, an avowed "erratic Marxist"...
| By: Renee Maltezou and John O'Donnell
German conservative says Greece may be better off outside euro BERLIN, July 5- Senior German conservative lawmaker Hans Michelbach told Reuters on Sunday that Greece might be better off outside the single currency after early referendum results showed the country was poised to reject euro zone bailout terms. "Now one has to ask the question whether Greece would not be better off outside the euro zone," said Michelbach, a...
WRAPUP 1-Greek minister: Europe can't afford to let Athens go under *Germany's Schaeuble says Greece might lose euro "temporarily". *Greece votes Sunday in referendum on aid deal. ATHENS, July 4- Europe will lose a trillion euros if it allows Greece to go under, the country's finance minister said on Saturday, accusing creditors of' terrorizing' Greeks into accepting austerity in a referendum on bailout terms.
| By: Lefteris Karagiannopoulos
WRAPUP 1-Greece seeks Eurogroup, ECB support after IMF default *Skepticism in euro zone about lending more to Greece. ATHENS/ BRUSSELS, July 1- Greece was appealing to its euro zone partners and the European Central Bank on Wednesday to keep it afloat after defaulting on its debt to the International Monetary Fund and losing frozen international bailout money. In Germany, Greece's biggest creditor, a senior lawmaker in...
| By: Lefteris Karagiannopoulos and Paul Taylor
Juno, Celgene's $1B cancer-fighting deal: CEO Hans Bishop, Juno Therapeutics CEO, discusses the company's strategic collaboration with Celgene to develop advance immunotherapies for patients with cancer and autoimmune diseases.
Celgene places $1B bet on Juno Therapeutics U.S. biotech giant Celgene has invested $1 billion in Juno Therapeutics in a move seen as a strong vote of confidence in a new generation of experimental cancer treatments, the FT reports.
Source: Financial Times
| By: David Crow
Now comes the SpaceX rocket whodunit: A complex mystery WASHINGTON- A rocket's dead, blown to bits in public view. After 18 straight successful launches, SpaceX's Falcon 9 rocket broke apart Sunday morning minutes after soaring away from Cape Canaveral, Florida. Russia also lost a supply shipment in April when its Progress capsule spun out of control.
Source: The Associated Press
| By: By SETH BORENSTEIN, AP Science Writer
UPDATE 1-Newspaper deletes Grexit quote erroneously attributed to Austria fin minister VIENNA, June 28- Austrian newspaper Die Presse removed a quote it had erroneously attributed to the country's finance minister from its website on Sunday saying the words actually formed part of a reporter's question. In the amended version of the interview, Schelling said a Grexit would only be possible if Athens first asked to leave the European Union and...
UPDATE 1-Rift with Greece sets Europe into uncharted territory *Euro zone, Greece face off after months of "poker". BRUSSELS, June 28- Europe's grand project to bind its nations into an unbreakable union by means of a common currency lurched into uncharted waters after EU governments refused funding to save Greece from defaulting on its debts. While finance ministers of the other 18 euro zone states chorused their insistence...
| By: Alastair Macdonald
Rift with Greece sets Europe into uncharted territory *Euro zone, Greece face off after months of "poker". BRUSSELS, June 28- Europe's grand project to bind its nations into an unbreakable union by means of a common currency lurched into uncharted waters after EU governments refused funding to save Greece from defaulting on its debts. While finance ministers of the other 18 euro zone states chorused their insistence...
| By: Alastair Macdonald